Clinical trials and RIRO.

J. A. Lee

DOI: https://doi.org/10.1016/S1470-2045(00)00087-5

IF: 54.433

2000-10-01

The Lancet Oncology

Abstract:

What problem does this paper attempt to address?

Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Shisheng Peng,Cong Tan,Lirong Du,Yanan Niu,Xiansheng Liu,Ruiying Wang

DOI: https://doi.org/10.1186/s12890-023-02602-5

2023-08-17

Abstract:Background: The fracture risk of patients with chronic obstructive pulmonary disease (COPD) treated with inhaled corticosteroids is controversial. And some large-scale randomized controlled trials have not solved this problem. The purpose of our systematic review and meta-analysis including 44 RCTs is to reveal the effect of inhaled corticosteroids on the fracture risk of COPD patients. Methods: Two reviewers independently retrieved randomized controlled trials of inhaled corticosteroids or combinations of inhaled corticosteroids in the treatment of COPD from PubMed, Embase, Medline, Cochrane Library, and Web of Science. The primary outcome was a fracture event. This study was registered at PROSPERO (CRD42022366778). Results: Forty-four RCTs were performed in 87,594 patients. Inhaled therapy containing ICSs (RR, 1.19; 95%CI, 1.04-1.37; P = 0.010), especially ICS/LABA (RR, 1.30; 95%CI, 1.10-1.53; P = 0.002) and triple therapy (RR, 1.49; 95%CI, 1.03-2.17; P = 0.04) were significantly associated with the increased risk of fracture in COPD patients when compared with inhaled therapy without ICSs. Subgroup analyses showed that treatment duration ≥ 12 months (RR, 1.19; 95%CI, 1.04-1.38; P = 0.01), budesonide therapy (RR, 1.64; 95%CI., 1.07-2.51; P = 0.02), fluticasone furoate therapy (RR, 1.37; 95%CI, 1.05-1.78; P = 0.02), mean age of study participants ≥ 65 (RR, 1.27; 95%CI, 1.01-1.61; P = 0.04), and GOLD stage III(RR, 1.18; 95%CI, 1.00-1.38; P = 0.04) were significantly associated with an increased risk of fracture. In addition, budesonide ≥ 320 ug bid via MDI (RR, 1.75; 95%CI, 1.07-2.87; P = 0.03) was significantly associated with the increased risk of fracture. Conclusion: Inhalation therapy with ICSs, especially ICS/LABA or triple therapy, increased the risk of fracture in patients with COPD compared with inhaled therapy without ICS. Treatment duration, mean age of participants, GOLD stage, drug dosage form, and drug dose participated in this association. Moreover, different inhalation devices of the same drug also had differences in risk of fracture.
The association between inhaled corticosteroid and osteoporosis and fracture

Cheng-Yi Wang,Chih-Cheng Lai

DOI: https://doi.org/10.1183/13993003.00216-2021

IF: 24.3

2021-06-01

European Respiratory Journal

Abstract:We read with great interest the study investigating the association between inhaled corticosteroid (ICS) and the risk of osteoporosis and fracture among COPD patients [1]. Multivariate analysis in this study demonstrated a significant dose–effect relationship between ICS and the risk of osteoporosis-related events. Compared to non-ICS users, high-dose ICS treatment was significantly associated with any osteoporosis-related event (risk ratio 1.52, 95% CI 1.24–1.62; while the corresponding estimate for low-dose ICS was 1.27, 95% CI 1.13–1.56) [1]. Overall, it is a well-designed study; however, we have one major and two minor concerns about the findings of this study.

respiratory system
Corticosteroid in Non-Covid-19 Induced Community-Acquired Pneumonia, a Meta-Analysis.

Jian Liu,Yongquan Dong,Jia Chen,Yuqing Jin,Yunqing Qiu,Lingtong Huang

DOI: https://doi.org/10.1016/j.hrtlng.2024.02.004

IF: 3.149

2024-01-01

Heart & Lung

Abstract:BACKGROUND:Corticosteroid treatment in non-COVID-19 induced Community-acquired pneumonia (CAP) remains inconclusive.OBJECTIVES:We aimed to assess the role of corticosteroid treatment in CAP.METHODS:We conducted a comprehensive search of online databases, including PubMed, Embase, and Cochrane, to identify articles published from January 1, 2000, to May 5, 2023. Double-blind RCTs were selected. Two authors screened studies and extracted data. The evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach.RESULTS:We analyzed data from 12 RCTs, involving 2446 patients. Corticosteroids therapy may reduce short-term mortality in patients with severe CAP (sCAP) and shorten the hospital length of stay in patients with CAP. Furthermore, corticosteroids treatment can decrease the risk of requiring mechanical ventilation, developing septic shock and multiple organ dysfunction syndrome (MODS). There were no significant differences between the corticosteroid and control groups concerning gastrointestinal bleeding and nosocomial infection. The use of corticosteroids could increase the risk of hyperglycemia.CONCLUSION:Corticosteroid treatment for sCAP has the potential to provide benefits in reducing short-term mortality, but this conclusion necessitates more evidence. Besides, we found no evidence that strongly prevents us from using corticosteroids in patients with sCAP or those at risk of progressing to sCAP.
Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

Hong Chen,Yulin Feng,Ke Wang,Jing Yang,Yuejun Du

DOI: https://doi.org/10.1186/s12890-020-01315-3

IF: 3.1

2020-10-28

BMC Pulmonary Medicine

Abstract:Abstract Background We aimed to assess the association between inhaled corticosteroids (ICSs) and the risk of upper respiratory tract infection (URTI) in patients with chronic obstructive pulmonary disease (COPD). Methods PubMed, Embase, Cochrane Library and Clinical Trials.gov were searched from inception to October 2019. Randomized controlled trials (RCTs) of any ICSs vs control for COPD with reporting of URTI as an adverse event were included. The study was registered with PROSPERO prospectively (#CRD42020153134). Results Seventeen RCTs (20,478 patients) were included. ICSs significantly increased the risk of URTI in COPD patients (RR, 1.13; 95% CI 1.03–1.24; P = 0.01; heterogeneity: I 2 = 7%). Futher subgroup analyses suggested that short-term use of ICSs increased the risk of URTI (RR, 1.29; 95% CI 1.06–1.56; P = 0.01; heterogeneity: I 2 = 14%) but not for long-term use (RR, 1.08; 95% CI 0.97–1.2; P = 0.14; heterogeneity: I 2 = 0%). Short-term use of high-dose fluticasone increased the risk of URTI (RR, 1.33; 95% CI 1.03–1.71; P = 0.03; heterogeneity: I 2 = 0%) but not for long-term use (RR, 1.12; 95% CI 0.97–1.29; P = 0.13; heterogeneity: I 2 = 50%). Medium-dose (RR, 0.97; 95% CI 0.71–1.32; P = 0.84; heterogeneity: I 2 = 0%) and low-dose (RR, 1.39; 95% CI 0.92–2.1; P = 0.12; heterogeneity: I 2 = 30%) fluticasone did not increase the risk of URTI regardless of duration. Neither mometasone (RR, 1.05; 95% CI 0.87–1.26; P = 0.61; heterogeneity: I 2 = 0%) nor budesonide (RR, 1.08; 95% CI 0.77–1.5; P = 0.67; heterogeneity: I 2 = 46%) increased the risk of URTI, regardless of dosage or duration. Conclusions Long-term use of ICSs does not increase the risk of URTI in patients with COPD. Short-term use of high-dose fluticasone increases the risk of URTI in patients with COPD, but not mometasone or budesonide.

respiratory system
Address e-mail security in the quality department.

P. Spath

2001-11-01

Abstract:
Adverse impacts of corticosteroid treatment on osteoporosis/osteopenia in adult asthmatics: A retrospective ICARUS cohort study

Junhyuk Chang,Hyun-Seob Jeon,Chungsoo Kim,ChulHyoung Park,Jae-Hyuk Jang,Youngsoo Lee,Eunyoung Lee,Rae Woong Park,Hae-Sim Park

DOI: https://doi.org/10.1016/j.jaip.2024.10.016

IF: 11.022

2024-10-26

The Journal of Allergy and Clinical Immunology In Practice

Abstract:Background and objectives Inhaled corticosteroid (ICS) and oral corticosteroid (OCS) are often used in asthma management. This study evaluated the long-term effect of ICS/OCS on osteoporosis, osteopenia, fractures, and bone metabolism in adult asthmatics in real-world clinical practice. Methods This is a retrospective study investigating de-identified electronic health records from Ajou University Medical Center (Korea). Adult asthmatics receiving maintenance ICS with/without OCS for at least 1 year were enrolled. They were classified into the high/low-dose of ICS or OCS groups. Primary outcomes (incidences of osteoporosis, osteopenia, and fractures) and secondary outcomes (drug prescription and laboratory values related to bone metabolism including albumin and alkaline phosphatase [ALP]) were compared after 5 years of follow-up. Results After propensity score matching, both high- and low-dose OCS groups included 468 patients, and high/low-dose ICS groups each comprised 1,252 patients. The risk of osteoporosis/major fracture was higher (hazard ratio [95% CI]; 2.00 [1.15-3.57]/3.03 [1.04-11.11]) in the high-dose OCS group (especially in females aged ≥50 years) than in the low-dose group, although the ICS groups showed no significant differences. The high-dose ICS group showed a higher risk of osteopenia (1.92 [1.05-3.70]) than the low-dose ICS group. The linear mixed model of laboratory values showed significantly decreased serum albumin and increased ALP in the high-dose OCS group than in the low-dose OCS group. Conclusions The results of this study suggest that long-term use of OCS can increase the risk of osteoporosis and osteoporosis-related fractures, while long-term use of ICS may increase the risk of osteopenia in adult asthmatics.

immunology,allergy
Risk of adverse reactions associated with inhaled corticosteroids for chronic obstructive pulmonary disease: A meta-analysis

Chenghe Lu,Xinghua Mao

DOI: https://doi.org/10.1097/md.0000000000036609

IF: 1.6

2024-01-20

Medicine

Abstract:Chronic obstructive pulmonary disease (COPD) is a common clinical respiratory disease with high morbidity and mortality, which not only damages human organs, but also brings psychological anxiety and burden to patients and their families. [ 1–3 ] There are two main classes of drugs commonly used in clinical practice, including inhaled glucocorticoids (ICS), bronchodilators, anti-inflammatory drugs, and expectorants. [ 1 ] In patients with COPD, ICS are helpful in lowering airway inflammation, nonspecific airway hyperresponsiveness, and airway obstruction. [ 4 ] The use of ICS with long-acting bronchodilators in the treatment of COPD has been shown to be more effective than using single agents in reducing patient symptoms, enhancing lung function, and preventing exacerbations. [ 5 ] Commonly used ICS include budesonide, fluticasone, fluticasone combined with salmeterol, and budesonide combined with formoterol. [ 6 ] Although the majority of studies have found that using ICS is generally safe, patients and their families are becoming more worried about ICS-related side effects include pneumonia, [ 7 ] oral Candida infections, [ 8 ] and renal suppression. [ 9 ] The relationship between ICS and specific adverse reactions still has to be further established because different investigations on whether ICS raises the likelihood of adverse reactions in COPD patients have produced contradictory results. ICS can be used effectively and optimally by ensuring the accuracy of the safety indicators in each study. Whereas other meta-studies on adverse effects of ICS for COPD have mostly focused on one type of adverse effects, we included more randomized controlled studies with meta-analysis of multiple adverse effects to assess the safety of ICS use in patients with COPD.

medicine, general & internal
Assessment of osteoporosis and fracture risk in people with interstitial lung disease, can we do better?

Chapman,L.,DAncona,G.,Ali,A.,Wright,A.,Clements,J.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4758

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Oral corticosteroids (OCS) have an essential role in the treatment of many respiratory conditions, including interstitial lung disease (ILD). However, their use increases patient risk of osteoporosis and fractures. This avoidable harm can be minimised by assessing patients against National Osteoporosis Guideline Group recommendations and where necessary, prescribing appropriate "bone protection". This study sought to investigate clinical practice at a tertiary ILD service in London. 123 sequential records were reviewed and 78 patients were found to be prescribed OCS. 65 met the criteria to receive bone protection (see table 1), but only 19 (29%) were prescribed appropriate bone protection (83% received calcium supplements, 91% vitamin D supplementation; 3% and 1% did not receive calcium/vitamin D supplements due to contraindications respectively). 2/19 stopped the OCS, but also had their bone protection stopped without reassessment of fragility risk, 1/19 had their bone protection therapy stopped despite ongoing high dose OCS. This cohort review highlights the need to improve identification of patients at risk of OCS-induced osteoporosis and support appropriate initiation and review of bone protective therapies.

respiratory system
Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study

Sung Hye Kong,Ae Jeong Jo,Chan Mi Park,Kyun Ik Park,Ji Eun Yun,Jung Hee Kim

DOI: https://doi.org/10.3803/EnM.2024.1990

2024-08-30

Abstract:Background: In this comprehensive retrospective nationwide cohort study, we examined the relationships between various asthma medications and bone health, utilizing data from the National Health Insurance Service database of South Korea. Methods: From 2015 to 2019, the relevant dataset included 168,611 individuals aged 66 years, among whom 8,747 were diagnosed with asthma. We focused on a subset of 6,173 patients, all 66-year-old women. Participants were categorized into four groups: nonusers of asthma medication (n=2,868), leukotriene antagonist users (n=2,281), inhaled corticosteroid (ICS) users (n=517), and those using a combination of ICS and long-acting beta-agonist (ICS+LABA) medication (n=507). The primary outcomes measured were the incidences of major osteoporotic fractures and hip fractures during the follow-up period. Results: Over 2.7 years of follow-up, 615 cases of major osteoporotic fractures and 96 cases of hip fractures were recorded. ICS users exhibited a heightened risk of both injuries, with hazard ratios of 1.38 (95% confidence interval [CI], 1.18 to 1.63; P<0.001) for major osteoporotic fractures and 1.56 (95% CI, 1.33 to 1.83; P<0.001) for hip fractures. Similarly elevated risks were observed in the ICS+LABA group. Notably, the risk associated with ICS was particularly pronounced among patients with osteopenia for both fracture types. Overall, the use of ICS, alone or in combination with LABA, in patients with asthma is associated with significantly increased risks of osteoporotic fractures, especially among those with osteopenia. Conclusion: These findings underscore the importance of considering bone health when managing asthma, especially in older patients and those with existing bone density issues.
Effects of asthma and inhaled corticosteroids in children on the ifnal adult height：a systemic review and Meta analysis

Lian-Hui CHEN,Shan-Shan CHEN,Li LIANG,Chang-Chong LI

DOI: https://doi.org/10.7499/j.issn.1008-8830.2015.11.018

2015-01-01

Abstract:ObjectiveTo evaluate the effects of asthma and inhaled corticosteroids (ICS) in children on the ifnal adult height.MethodsA search was performed to collect studies evaluating the relationship between asthma and ICS in children and the ifnal adult height in PubMed, BCI, EMbase, Web of Science, CNKI and Wanfang databases, then a systemic review and Meta analysis were conducted.ResultsSix studies evaluating the relationship between childhood asthma and the ifnal adult height were enrolled. Three of them indicated that the ifnal adult height was not inlfuenced by childhood asthma. Two of them suggested a mild effect, and the effect was correlated with severity of childhood asthma. One of them indicated that a lower final adult height related to childhhod asthma was found only in black females without a high school education. Four studies evaluating the relationship between ICS and the ifnal adult height were included. Compared with the non-ICS treatment group, healthy control group and the target height, ICS treatment had no effects on the ifnal adult height.ConclusionsChildhood asthma does not or only mildly decrease the ifnal adult height. ICS treatment does not signiifcantly affect the ifnal adult height.
Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis

Tyler Pitre,Michel Kiflen,Terence Ho,Luis M Seijo,Dena Zeraatkar,Juan P de Torres

DOI: https://doi.org/10.1186/s12890-022-02072-1

2022-07-17

Abstract:Background: There has been debate on whether inhaled corticosteroids (ICS) reduce the incidence of lung cancer amongst patients with Chronic Obstructive Lung Disease (COPD). We aimed to perform a systematic review and dose-response meta-analysis on available observational data. Methods: We performed both a dose response and high versus low random effects meta-analysis on observational studies measuring whether lung cancer incidence was lower in patients using ICS with COPD. We report relative risk (RR) with 95% confidence intervals (CI), as well as risk difference. We use the GRADE framework to report our results. Results: Our dose-response suggested a reduction in the incidence of lung cancer for every 500 ug/day of fluticasone equivalent ICS (RR 0.82 [95% 0.68-0.95]). Using a baseline risk of 7.2%, we calculated risk difference of 14 fewer cases per 1000 ([95% CI 24.7-3.8 fewer]). Similarly, our results suggested that for every 1000 ug/day of fluticasone equivalent ICS, there was a larger reduction in incidence of lung cancer (RR 0.68 [0.44-0.93]), with a risk difference of 24.7 fewer cases per 1000 ([95% CI 43.2-5.4 fewer]). The certainty of the evidence was low to very low, due to risk of bias and inconsistency. Conclusion: There may be a reduction in the incidence for lung cancer in COPD patients who use ICS. However, the quality of the evidence is low to very low, therefore, we are limited in making strong claims about the true effect of ICS on lung cancer incidence.
Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis

Amare Abera Tareke,Wondwosen Debebe,Addis Alem,Nebiyou Simegnew Bayileyegn,Taddese Alemu Zerfu,Andualem Mossie Ayana

DOI: https://doi.org/10.1155/2022/9799858

2022-08-21

Abstract:Background: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic review and meta-analysis to determine the role of ICS in the risk of lung cancer among COPD patients. Methods: A comprehensive search of PubMed, Science Direct, Google Scholar, and Cochrane library and a manual search of the list of references were conducted. Studies with cohort, case-control, and randomized clinical trial designs for any ICS use reporting the incidence/hazard ratio (HR) of lung cancer were included. The random-effects model was used to pool hazard ratios. Subgroup analysis and metaregression analysis were employed. Funnel plot and Egger regression test were used to assess publication bias. Results: Combining the results of 14 observations, the pooled HR for cancer risk reduction was 0.69 (95% CI 0.59-0.79), p value ≤ 0.001. The use of ICS in COPD patients showed a 31% reduction in the risk of lung cancer. Subgroup meta-analysis showed a significant reduction in the risk of lung cancer as well. Conclusion: The use of ICS in COPD patients reduces the risk of lung cancer. The risk reduction was independent of smoking status and latency period. Future studies should focus on the optimum dose and controlling confounders like asthma.
The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis

Chao-Hsien Chen,Ching-Yi Chen,Chih-Cheng Lai,Ya-Hui Wang,Kuang-Hung Chen,Cheng-Yi Wang,Yu-Feng Wei,Pin-Kuei Fu

DOI: https://doi.org/10.1016/j.jiph.2023.03.019

IF: 7.537

2023-04-01

Journal of Infection and Public Health

Abstract:Background The effect of inhaled corticosteroid (ICS) on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is unclear. Methods We performed a systematic review and meta-analysis of clinical studies that assessed the association between the use of ICS and the risk of SARS-COV-2 infection. PubMed, Web of Science, Scopus, Cochrane Library and Google Scholar were searched to January 1st, 2023. ROBINS-I was used to assess risk of bias of included studies. The outcome of interest was the risk of SARS-COV-2 infection in patients and odds ratio (OR) with 95% confidence interval (95% CI) were calculated using Comprehensive Meta-analysis software version 3. Results Twelve studies involving seven observational cohort studies, three case-control studies, and two cross-sectional studies were included in this meta-analysis. Overall, compared to non-ICS use, the pooled odds ratio (OR) of the risk of SARS-COV-2 infection was 0.997 (95% confidence interval [CI] 0.664–1.499; p = 0.987) for patients with ICS use. Subgroup analyses demonstrated no statistical significance in the increased risk of SARS-COV-2 infection in patients with ICS monotherapy or in combination with bronchodilators (pooled OR=1.408; 95% CI=0.693–2.858; p = 0.344 in ICS monotherapy, and pooled OR=1.225; 95% CI=0.533–2.815; p = 0.633 in ICS combination, respectively). In addition, no significant association was observed between ICS use and the risk of SARS-COV-2 infection for patients with COPD (pooled OR=0.715; 95% CI=0.415–1.230; p = 0.225) and asthma (pooled OR=1.081; 95% CI=0.970–1.206; p = 0.160). Conclusions The use of ICS, either monotherapy or in combination with bronchodilators, does not have impact on the risk of SARS-COV-2 infection.

infectious diseases,public, environmental & occupational health
FURTHER OBSERVATIONS ON THE OVARIAN ASCORBIC ACID DEPLETION TESTS FOR LUTEINIZING HORMONE.

E. Bell,J. Loraine,S. Mukerji,P. Visutakul

DOI: https://doi.org/10.1677/JOE.0.0320001

1965-04-01

Journal of Endocrinology

Abstract:
[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].

P. Baudouy,P. Lombrail,I. Azancot,A. Piekarski,É. Martin,R. Slama

1983-10-01

Abstract:Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy. Infiltrative, congestive and restrictive cardiomyopathy was diagnosed in the presence of global cardiomegaly, electrocardiographic changes (microvoltage, diffuse ST-T wave changes), echocardiographic appearances (dilatation of the left ventricle, with hypertrophic and hypokinetic walls), and hemodynamic signs of adiastole with equalisation of filling pressures at 15 mmHg and a cardiac index of 1,88 l/min/m2. Cardiac haemochromatosis was confirmed by the laboratory (serum iron: 35 mumol/l; siderophilin saturation: 100 p. 100; serum ferritin: 1854 ng/ml; induced siderouria: 51 mg/24 hours) and histological findings (endomyocardial biopsy showing pigment overload). The absence of a family history, of homozygote A3 antigen, of diabetes, of iron overload on hepatic biopsy one year previously, excluded the diagnosis of familial idiopathic haemochromatosis. A secondary form of the disease was diagnosed on a possible genetic predisposition (heterozygote A3 antigen) and on environmental factors (blood transfusions, iron therapy, cirrhosis, alcoholism and perhaps the porto-caval anastamosis. Cardiac haemochromatosis was cured in this case by iron chelating therapy comprising daily subcutaneous infusions of 2 g of desferrioxamine for 2 months. The cure was confirmed by regression of the signs of clinical cardiac failure and of cardiomegaly, the increase in QRS voltages and the near normalisation of the hemodynamic and laboratory findings.
The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice

Ian M Adcock,Surya P Bhatt,Ronald Balkissoon,Robert A Wise

DOI: https://doi.org/10.1016/j.amjmed.2021.09.006

Abstract:The use of inhaled corticosteroids (ICS) in combination with inhaled bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is a common practice in primary care settings. However, ICS-containing therapies may be less effective in patients with COPD compared with asthma, and in individuals with COPD who continue to smoke cigarettes. Preclinical studies suggest that inflammation in COPD is very different from in asthma. Glucocorticoid receptor functioning and other innate anti-inflammatory mechanisms are altered in cells exposed to cigarette smoke. COPD may be relatively insensitive to ICS, especially in individuals who continue to smoke. ICS-containing therapies in patients with asthma who continue to smoke may also be less effective compared with patients who do not smoke. ICS-containing therapies may be inappropriately used in some patients with COPD, and their long-term use is associated with an increased risk for side effects, including pneumonia and bone fractures in some patients. Treatment for patients with COPD should be carefully evaluated, and anti-inflammatory/bronchodilatory strategies should be chosen based on individual patient characteristics and recommendations in current guidelines.
Inhaled corticosteroids in COPD: risk and benefits

Christer Janson

DOI: https://doi.org/10.1136/thoraxjnl-2021-217930

2021-09-23

Thorax

Abstract:COPD is a progressive disease where airway inflammation plays an important part. Previously, there were large expectations that regular anti-inflammatory treatment with inhaled corticosteroids (ICS) might help stop disease progression. In 2007, the much-anticipated result from the Towards a Revolution in COPD Health study (TORCH) was published.1 The primary objective of TORCH was to see if the combination of the long-acting beta-agonist (LABA) and ICS would reduce mortality among patients with COPD. The study did not find a statistically significant survival benefit of the ICS/LABA treatment compared with placebo. However, somewhat unexpectedly, they found that pneumonia was more common in the treatment arms that had received ICS. In the group with ICS/LABA, 20% of the patients had at least one event of pneumonia compared with 12% in the placebo group. That ICS increases the risk of pneumonia in COPD has been confirmed in many subsequent randomised controlled...

respiratory system
[Effects of drugs on preventing recurrent myocardial infarction in patients with healed myocardial infarction].

K. Ishikawa,K. Kanamasa,J. Hama,I. Ogawa,T. Takenaka,T. Naito,N. Kamata,S. Nakai,T. Yamamoto,M. Oyaizu

DOI: https://doi.org/10.1253/JCJ.58.SUPPLEMENTIV_1288

1995-01-20

Japanese Circulation Journal

Abstract:
The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis

Chao-Hsien Chen,Cheng-Yi Wang,Ching-Yi Chen,Ya-Hui Wang,Kuang-Hung Chen,Chih-Cheng Lai,Yu-Feng Wei,Pin-Kuei Fu

DOI: https://doi.org/10.1371/journal.pone.0295366

IF: 3.7

2024-01-19

PLoS ONE

Abstract:The influence of inhaled corticosteroids (ICS) on COVID-19 outcomes remains uncertain. To address this, we conducted a systematic review and meta-analysis, analyzing 30 studies, to investigate the impact of ICS on patients with COVID-19. Our study focused on various outcomes, including mortality risk, hospitalization, admission to the intensive care unit (ICU), mechanical ventilation (MV) utilization, and length of hospital stay. Additionally, we conducted a subgroup analysis to assess the effect of ICS on patients with chronic obstructive pulmonary disease (COPD) and asthma. Our findings suggest that the prior use of ICS did not lead to significant differences in mortality risk, ICU admission, hospitalization, or MV utilization between individuals who had used ICS previously and those who had not. However, in the subgroup analysis of patients with COPD, prior ICS use was associated with a lower risk of mortality compared to non-users (OR, 0.95; 95% CI, 0.90-1.00). Overall, while the use of ICS did not significantly affect COVID-19 outcomes in general, it may have beneficial effects specifically for patients with COPD. Nevertheless, more research is needed to establish a definitive conclusion on the role of ICS in COVID-19 treatment. PROSPERO registration number: CRD42021279429.
Early detection of airway abnormalities in a selected group of population.

P. Kristufek,K. Virsik,A. Bajan,L. Badalik,V. Dreviankova

1976-05-01

Abstract:Functional data were collected from 5,746 males from a country region, whose ages ranged from 14 to 65 years. Out of this population we excluded a group of 466 males (9%) who had abnormal results of traditional pulmonary function screening tests (FVC less than 80% reference values or FEV1% FVC less than 70%) and chose a group of 1,092 males (19%) with normal values for the above two parameters but with abnormal forced mid-expiratory flow. In randomly selected persons of the second group we found frequency dependent dynamic compliance (100%), abnormal maximum expiratory flow at 25% of vital capacity (98%), increased residual volume (76%), decreased maximum expiratory flow at 50% of vital capacity (67%), and increased closing capacity (57%); on the contrary static complicane and airway resistance were normal. To account for these results we suppose that measurement of forced mid-expiratory flow, abnormal values of which we obtained in practically one fifth of the experimental population, could represent, in agreement with other reports, a suitable screening test for first or early detection of airway abnormalities.

Clinical trials and RIRO.

Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

The association between inhaled corticosteroid and osteoporosis and fracture

Corticosteroid in Non-Covid-19 Induced Community-Acquired Pneumonia, a Meta-Analysis.

Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

Address e-mail security in the quality department.

Adverse impacts of corticosteroid treatment on osteoporosis/osteopenia in adult asthmatics: A retrospective ICARUS cohort study

Risk of adverse reactions associated with inhaled corticosteroids for chronic obstructive pulmonary disease: A meta-analysis

Assessment of osteoporosis and fracture risk in people with interstitial lung disease, can we do better?

Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study

Effects of asthma and inhaled corticosteroids in children on the ifnal adult height：a systemic review and Meta analysis

Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis

Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis

The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis

FURTHER OBSERVATIONS ON THE OVARIAN ASCORBIC ACID DEPLETION TESTS FOR LUTEINIZING HORMONE.

[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].

The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice

Inhaled corticosteroids in COPD: risk and benefits

[Effects of drugs on preventing recurrent myocardial infarction in patients with healed myocardial infarction].

The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis

Early detection of airway abnormalities in a selected group of population.